Community Practice Connections™: Understanding Cold Agglutinin Disease: How Do Emerging Treatment Options Have the Potential to Transform Patient Outcomes?

Released On
February 26, 2021

Expires On
February 26, 2022

Media Type
Internet

Completion Time
90 minutes

Specialty
Critical Care, Hematology-Oncology, Hospitalist

Topic(s)
Hematology

Scroll to the Bottom of this Information to Begin this Course

This activity is provided by Physicians’ Education Resource®, LLC.

This activity is supported by an educational grant from Sanofi Genzyme.

Credit Available

  • Physicians — maximum of 1.5 AMA PRA Category 1 Credit(s)

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

This educational activity is directed toward medical hematologists and other health care professionals interested in the latest advances in the treatment of patients with CAD. Fellows, researchers, primary care physicians, nurses, nurse practitioners, physician assistants, and other health care professionals interested in the treatment of patients with hematologic diseases are also invited to participate.

Activity Overview

Cold agglutinin disease (CAD) is a serious condition with unpredictable anemia events ranging in occurrence and severity, and which can be debilitating and potentially life-threatening. More than half of the affected patients may require transfusions, and a large majority need treatment; but options are limited, and none are specifically approved for CAD. However, novel complement-directed therapies are currently in development, which hold promise for this autoimmune hemolytic anemia.

This Community Practice Connections™ program provides an in-depth review of some of the key highlights from the live virtual symposium held on December 4, 2020. This unique and engaging multimedia activity is ideal for the community-based clinician and focuses on the practical aspects of managing patients with CAD, while placing recent clinical trial data into a clinical context. The program is designed for those who did not attend the live meeting and would help to reinforce learnings for those who did.

Learning Objectives

Upon completion of this activity, you should be better prepared to:

  • Discuss the impact of cold agglutinin disease (CAD) on patients
  • Explain the role of the complement system, which leads to the recognition of CAD as a distinct clinical entity
  • Identify typical and atypical clinical manifestations of CAD and apply effective disease-specific assessments
  • Describe the role of complement-mediated therapies based on current efficacy and safety data of new and emerging agents for the treatment of patients with CAD

Faculty

FACULTY_NAME

Alexander Röth, MD

Physician, Department of Hematology
West German Cancer Center
University Hospital Essen
Essen, Germany

FACULTY_NAME

Catherine Broome, MD

Associate Professor of Medicine
Georgetown University
Lombardi Cancer Center
Washington, DC

FACULTY_NAME

Bernd Jilma

Professor and Section Head
Professor of Clinical Pharmacology & Internal Medicine
Medical University of Vienna
Vienna, Austria

FACULTY_NAME

Ilene Ceil Weitz, MD

Professor of Clinical Medicine
Jane Anne Nohl Division of Hematology
Keck-USC School of Medicine
Los Angeles, CA

Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures of Conflicts of Interest

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible entities.

Alexander Röth, MD has no relevant financial relationships with commercial interests to disclose.

Catherine Broome, MD has no relevant financial relationships with commercial interests to disclose.

Bernd Jilma has no relevant financial relationships with commercial interests to disclose.

Ilene Ceil Weitz, MD has no relevant financial relationships with commercial interests to disclose.

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Instructions for Participation and Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.
You may immediately download your certificate.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.